Chiron platelet testing
This article was originally published in The Gray Sheet
Executive Summary
Firm expects 510(k) clearance for platelet bacteria detection within 12-18 months, following Jan. 5 licensure of the technology from Canadian firm Infectio Diagnostic. Chiron first will seek FDA go-ahead for use in quality control testing, which would satisfy the forthcoming American Association of Blood Banks standard, effective in March. The nucleic acid test is being designed to provide same-day results - valuable given the limited five-day shelf life of platelets, and is superior to competitors Pall and Biomerieux, whose tests require 48 hours, according to Chiron. The firm believes it is well positioned for immediate success in the estimated $100 mil. market due to the ubiquity of the Procleix platform in blood banks. However, the platelet test will require a separate platform, yet to be determined...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.